Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

The facility’s products will include biologic drugs and a new, easier-to-use version of Keytruda, the company’s blockbuster cancer drug. The plant marks Merck’s first in-house manufacturing ...

Merck & Co., Inc. (NYSE ... A variety of vaccinations and veterinary pharmaceutical products are developed, discovered, produced, and marketed by its Animal Health sector. The company's sales ...

Key Takeaways For Merck & Co in the Pharmaceuticals industry, the high PE ratio suggests the stock is relatively expensive compared to peers. The low PB and PS ratios indicate potential ...